Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review

Table 4 Biologic management in inflammatory bowel disease patients

Ref.	Biology	Diagnosis, n	Therapeutic stage	Therapeutic course	Injection dose	Injection frequency
Chaparro et al[12], 2018	ADA	IBD 94	Maintenance	At least 6 mo	/	/
Ungar et al[28], 2016	IFX	IBD 88	Maintenance	At least 6 mo	/	/
Yarur et al[29], 2016	ADA	IBD 67	Induction	Less than 1 mo	/	/
Roblin et al[26], 2014	IFX	IBD 78	Induction	Less than 2 mo	/	/
Chaparro et al[12], 2018	ADA	IBD 66	Maintenance	At least 12 wk	160 mg, 80 mg, 40 mg	Induction: 160 mg at week 0 and 80 mg at week 2; Maintenance: 2 weekly (47 patients), weekly (19 patients)
Ungar et al[28], 2016	ADA	IBD 40	Maintenance	/	/	2 weekly or weekly
Morita et al[18], 2016	ADA	UC 33	Induction and Maintenance	/	160 mg, 80 mg, 40 mg	160 mg at week 0, 80 mg at week 2, and 40 mg 2 weekly
	IFX	UC 31	Induction and maintenance	/	5 mg/kg	At weeks 0, 2, 6 and 8 weekly later
Morita et al[19], 2016	ADA	CD 42	Maintenance	At least 6 mo	40 mg	2 weekly
Strik et al[27], 2019	ADA	PfCD 19	Maintenance	/	40 mg	2 weekly (11 patients), Weekly (8 patients)
	IFX	PfCD 47	Maintenance	/	5 mg/kg, 10 mg/kg	5 mg/kg 8 weekly (27 patients), 5 mg/kg 6 weekly (10 patients)5 mg/kg 4 weekly (3 patients), 10 mg/kg 8 weekly (4 patients); 10 mg/kg 6 weekly (2 patients), 10 mg/kg 4 weekly (1 patients)
Plevris et al[24], 2020	ADA	PfCD 35	Maintenance	At least 24 wk	40 mg	Weekly (17 patients), Fortnightly (18 patients)
	IFX	PfCD 29	Maintenance	At least 24 wk	5 mg/kg, 10 mg/kg	5 mg/kg 8 weekly (16 patients), 5 mg/kg 6 weekly (7 patients); 10 mg/kg 8 weekly (3 patients), 10 mg/kg 6 weekly (3 patients)
Zittan et al[30], 2016	ADA	CD 60	Maintenance	/	40 mg or not	40 mg (53 patients), other than 40 mg (7 patients); 2 weekly (35 patients), other than 2 weekly (25 patients)
Juncadella et al[16], 2018	ADA	IBD 98	Maintenance	/	40 mg or not	40 mg 2 weekly (59 patients), other than 40 mg 2 weekly (36 patients)
Papamichael et al[20], 2017	ADA	UC 43	Induction	14 wk	160 mg, 80 mg, 40 mg	160 mg at week 0, 80 mg at week 2, 40 mg 2 weekly or weekly from week 4, or 80 mg 2 weekly or weekly from week 4
Feng et al[14], 2019	IFX	CD 141	Maintenance	At least 14 wk	5 mg/kg	5 mg/kg at weeks 0, 2, 6 and thereafter every 8 wk during the study period (week 30)
Papamichael et al[22], 2018	IFX	UC 56	Maintenance	/	/	/
Papamichael et al[21], 2018	IFX	CD 110	Maintenance	/	5 mg/kg or not	5 mg/kg 8 weekly (63 patients), other than 5 mg/kg 8 weekly (47 patients)
Papamichael et al[23], 2016	IFX	UC 101	Induction	14 wk	/	/
Dreesen et al[31], 2020	IFX	CD 116	Induction and maintenance	54 wk	5 mg/kg	Induction: 5 mg/kg at week 0, 2, 6; Maintenance: 5 mg/kg, 7.5 mg/kg, or 10 mg/kg at week 14 and later
Imaeda et al[15], 2014	IFX	CD 45	Maintenance	At least 6 mo	5 mg/kg, 10 mg/kg	5 mg/kg 8 weekly (37 patients), 10 mg/kg 8 weekly (8 patients)
EI-Matary et al[32], 2019	IFX	PfCD 52	/	/	5 mg/kg or more	5 mg/kg/dose, often rounded up to the nearest 100 mg at weeks 0, 2, 6; Dose 4 was received at a median time interval following the third dose
Kang et al[17], 2019	IFX	PCD 105	Maintenance	/	/	/
Hanzel et al[33], 2019	VDZ	IBD 51	Induction and maintenance	54 wk	300 mg	Induction: At weeks 0, 2, 6, 10; Maintenance: 4 weekly or 8 weekly from week 14 onwards
Dreesen et al[13], 2018	VDZ	UC 66; CD 113	Induction and maintenance	22 wk	300 mg	Induction: At weeks 0, 2, 6 (179 IBD patients), At week 10 (102 CD patients); Maintenance: 8 weekly (162 IBD patients), 4 weekly (4 UC and 13 CD patients)
Pouillon et al[25], 2019	VDZ	UC 31	Maintenance	/	300 mg	8 weekly (19 samples) or 4 weekly (16 samples)
Yacoub et al[34], 2018	VDZ	CD 39; UC43	Induction and maintenance	52 wk	300 mg	Induction: At weeks 0, 2, 6; Maintenance: 4 weekly or 8 weekly from week 14 onwards

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; ADA: Adalimumab; VDZ: Vedolizumab; PFCD: Perianal fistula Crohn’s disease.